Improved understanding of the biological heterogeneity of breast cancer (BC) has facilitated the development of more effective and personalized approaches to treatment. This study describes real-world evidence on treatment patterns and outcomes for a population-based cohort of patients with human epidermal growth factor receptor (HER2) IHC0 and -low BC with de novo or recurrent disease from Alberta, Canada. Patients 18+ years old diagnosed with HER2 IHC0/-low, de novo/recurrent BC from 2010 to 2019 were identified using Alberta’s cancer registry. Analyses of these patients’ existing electronic medical records and administrative claims data were conducted to examine patient characteristics, treatment patterns, and survival outcomes. A total of 3413 patients were included in the study, of which 72.10% initiated first line hormonal and non-hormonal systemic therapy. The 1-year overall survival (OS) was 81.09% [95% CI, 79.52–82.69]. Recurrent patients had a higher OS compared to de novo patients: 54.30 months [95% CI, 47.80–61.90] vs. 31.5 months [95% CI, 28.40–35.90], respectively. Median OS was 43.4 months [95% CI, 40.70–47.10] and 35.80 months [95% CI, 29.00–41.70] among patients with HER2-low and HER2 IHC0 cancer, respectively. The study results provide real-world evidence regarding the clinical outcomes of HER2 IHC0/-low and de novo/recurrent disease.
对乳腺癌生物学异质性认识的深化，推动了更有效、个体化治疗策略的发展。本研究基于加拿大阿尔伯塔省人群队列，描述了人表皮生长因子受体2（HER2）免疫组化评分为0分与低表达、初发或复发乳腺癌患者的真实世界治疗模式与结局数据。通过阿尔伯塔省癌症登记系统，我们纳入了2010年至2019年间确诊的18岁以上HER2免疫组化0分/低表达、初发/复发乳腺癌患者。通过分析现有电子病历与行政理赔数据，我们系统评估了患者特征、治疗模式及生存结局。研究共纳入3413例患者，其中72.10%启动了首线激素或非激素全身治疗。1年总生存率为81.09%[95% CI, 79.52–82.69]。复发患者较初发患者总生存期更长：分别为54.30个月[95% CI, 47.80–61.90]对比31.5个月[95% CI, 28.40–35.90]。HER2低表达与HER2免疫组化0分患者的中位总生存期分别为43.4个月[95% CI, 40.70–47.10]与35.80个月[95% CI, 29.00–41.70]。本研究结果为HER2免疫组化0分/低表达及初发/复发乳腺癌的临床结局提供了真实世界证据。
肿瘤(癌症)患者之家